2017_SBRT_Course Book

Unresectable CRLM Local treatment

Progression survival

Overall survival

Median follow up: 9.7 years. 77% patients had died (65.0% CMT vs 90% systemic treatment arm) Significant difference in OS for CMT arm (HR 0.58, 95% CI 0.38 to 0.88, P .01) Median OS of 45.6 months in CMT arm versus 40.5 months in standard arm 3-, 5- and 8- year OS were 57%, 43% and 36% in CMT arm versus 55%, 30% and 9% in the systemic treatment arm

Ruers T, JNCI 2917